FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections

EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777

WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy

India highlights need for global cooperation to address AMR threat at UNGA

AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine

Bayer awards incubator opportunity to Genvor

Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

Gavi outlines plans to support access to new vaccines

The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030

Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam

DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable